Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults

NCT05517122 | Completed

• 1 other identifier: 2201NR
• Study Type: interventional
• Target: 68
• Locations: 1 country
• Sites: 1

Brief Summary

Nicotinamide adenine dinucleotide (NAD) is a coenzyme playing a central role in human metabolic pathways. A recognized approach to increase NAD level is through oral supplementation of its precursors promoting NAD synthesis in vivo. NAD precursors exist in multiple forms. However, it is unclear how the various precursors compare in their ability to increase NAD levels in human blood. The purpose of this study is to compare the effect of 3 NAD precursors on whole blood NAD metabolome.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Determine the extent of increase in NAD+ level in whole blood, for each NAD+ precursor (NAM, NR and NMN) compared to placebo

  Measure the changes in whole blood NAD+ level interventions vs placebo: NAM vs placebo, NR vs placebo, NMN versus placebo by quantitative liquid chromatography-mass spectroscopy

  at Day 14

• Compare the extent of increase in NAD+ level in whole blood across the 3 NAD+ precursors (NAM, NR and NMN)

  Measure the changes in whole blood NAD+ level across interventions: NAM vs NR, NAM vs NMN, NR vs NMN by quantitative liquid chromatography-mass spectroscopy

  at Day 14

Secondary Outcomes (2)

• Determine the extent the NAD+ precursors(NAM, NR and NMN) affect the NAD metabolome in whole blood compared to placebo

  over 4 hours at Day 1 and at Day 14.

• Compare the extent the NAD+ precursors (NAM, NR and NMN) affect the NAD+ metabolome in whole blood.

  over 4 hours at Day 1 and at Day 14.

Other Outcomes (2)

• Comparer the extend the NAD+ precursors (NAM, NR and NMN) affect the NAD+ metabolome in in plasma.

  over 4 hours at Day 1 and at Day 14.

• Comparer the extend the NAD+ precursors (NAM, NR and NMN) affect the NAD+ metabolome in urine

  at baseline Day 14 versus Day 1

Study Arms (4)

Nicotinamide (NAM)

EXPERIMENTAL

Dietary Supplement: Nicotinamide (NAM)

Nicotinamide Riboside (NR)

EXPERIMENTAL

Dietary Supplement: Nicotinamide Riboside (NR)

Nicotinamide Mono Nucleotide (NMN)

EXPERIMENTAL

Dietary Supplement: Nicotinamide Mono Nucleotide (NMN)

Microcrystalline cellulose

PLACEBO COMPARATOR

Dietary Supplement: Microcrystalline cellulose

Interventions

Nicotinamide (NAM) DIETARY_SUPPLEMENT

500 mg a day

Nicotinamide (NAM)

Nicotinamide Riboside (NR) DIETARY_SUPPLEMENT

1000 mg a day

Nicotinamide Riboside (NR)

Nicotinamide Mono Nucleotide (NMN) DIETARY_SUPPLEMENT

1000 mg a day

Nicotinamide Mono Nucleotide (NMN)

Microcrystalline cellulose DIETARY_SUPPLEMENT

500 mg a day

Microcrystalline cellulose

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male and female aged 18-50 years, inclusive, at enrolment
• Body mass index (BMI) between 18.5 to 27.0 kg/m².
• Able to understand and to sign a written informed consent prior to study enrolment.
• Willing and able to comply with the requirements for participation in this study.

You may not qualify if:

• Known history of allergy or intolerance to the investigational products.
• Any chronic medical condition and/or history of significant medical condition, which in the opinion of the site physician/ investigator may risk participant wellbeing/ safety, impede participant compliance with study procedures or ability to complete the study and/ or could confound the primary objectives of the study.
• Any acute illness or any recent medical intervention including vaccination within 14 days before the first dose of investigational product.
• Female participants who are pregnant or intending to become pregnant, lactating and/or breastfeeding. Women of childbearing potential who are not currently using medically effective forms of contraception.
• Use of prescription drugs known to potentially interact with NAD precursors within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
• Use of multivitamin/ multimineral supplements, NAD+ precursor supplementation (e.g., niacin, nicotinic acid or niacinamide), L-tryptophan supplementation and/ or any over-the- counter (OTC) medication promoting "healthy aging" or "anti-aging" or "longevity" up to 30 days before first dose of investigational product.
• On a self-restricted diet, controlled diet or special therapeutic diet up to 30 days before first dose of investigational product.
• Average alcohol consumption greater than 2 standard drinks per day over a week for males, and greater than 1 standard drink per day over a week for females. One standard drink contains 10-12 g of ethanol. Examples of standard drinks are one beer can (300 ml), one glass of wine (100 ml) or one glass of schnaps (30 ml).
• Current smoker (e.g., cigarette, tobacco, cannabis) who exceeds 5 cigarettes per week.
• Performing shift work or trans-meridian travel greater than two time zones within 14 days prior to the first dose of investigational product.
• Currently participating in another research study.
• Family or hierarchical relationships with the Clinical Innovation Lab (CIL) team.

Sponsors & Collaborators

• Société des Produits Nestlé (SPN): lead

Study Sites (1)

Nestlé Clinical Innovation Lab

Lausanne, Canton of Vaud, 1000, Switzerland

Location

Related Publications (1)

• Christen S, Redeuil K, Goulet L, Giner MP, Breton I, Rota R, Frezal A, Nazari A, Van den Abbeele P, Godin JP, Nutten S, Cuenoud B. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026 Jan 15. doi: 10.1038/s42255-025-01421-8. Online ahead of print.

  PMID: 41540253 DERIVED

MeSH Terms

Interventions

Niacinamide; nicotinamide-beta-riboside; microcrystalline cellulose

Intervention Hierarchy (Ancestors)

Nicotinic Acids; Acids, Heterocyclic; Heterocyclic Compounds; Pyridines; Heterocyclic Compounds, 1-Ring

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 4, 2022
• First Posted: August 26, 2022
• Study Start: July 12, 2022
• Primary Completion: November 24, 2022
• Study Completion: November 24, 2022
• Last Updated: April 24, 2025

Record last verified: 2025-04

Locations

CH (1)